IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas
- Conditions
- Squamous Cell Carcinoma
- Registration Number
- NCT04224389
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Brief Summary
Compare patients' feelings in terms of swallowing ability assessed by the overall score of MD Anderson Dysphagia Inventory (MDADI) 2 years after starting treatment between patients who have been treated with IMRT and those who were treated by transoral surgery for a squamous cell carcinoma of the early stage oropharynx.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 150
- Age ≥ 18 years old
- ECOG performance status 0-2
- Histologically confirmed squamous cell carcinoma
- Primitive localization of the oropharynx on the tonsil compartment or the tongue base
- p16 or HPV status available
- TNM classification AJCC7th T1 or T2
- TNM classification AJCC7th N0 or N1
- Patient and tumor that can be treated by radiotherapy or by transoral surgery
- Patient who has not objected to participate after being informed about the study. The patient must be able and willing to cooperate in follow-up and study visits
- Severe medical comorbidity or other contraindication to radiotherapy or surgery
- Primary tumor or unresectable lymphadenopathy
- Metastatic disease
- History of squamous cell carcinoma of the head and neck within 5 years
- History of radiation therapy to the head and neck
- Inability to undergo or complete radiation therapy follow-up consultations
- History of cancer except free of any disease for at least 5 years, with the exception of non-melanoma skin cancers
- Inability to complete questionnaires
- Pregnant or lactating woman
- Patient under tutorship or curatorship, deprived of liberty or unable to do so to express consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MD Anderson Dysphagia Inventory (MDADI) global score 2 years after inclusion Score goes from 20 to 100. A higher score means a better ability to swallow
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (16)
Centre Hospitalier InterCommunal
🇫🇷Créteil, France
Centre Oscar Lambret
🇫🇷Lille, France
Hôpital la Croix Rousse
🇫🇷Lyon, France
Centre Léon Bérard
🇫🇷Lyon, France
CHU Conception
🇫🇷Marseille, France
CHU Montpellier
🇫🇷Montpellier, France
CHU Nantes - Hôtel Dieu
🇫🇷Nantes, France
Institut Universitaire de la face et du cou
🇫🇷Nice, France
Hôpital Européen Georges Pompidou
🇫🇷Paris, France
CHU Reims
🇫🇷Reims, France
Scroll for more (6 remaining)Centre Hospitalier InterCommunal🇫🇷Créteil, FranceHéloïse DE KERMADEC, MDContact